236 related articles for article (PubMed ID: 21339203)
1. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.
Li R; Zhu W; Huang P; Ding C; Tang Y; Lian P; Huang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):730-738. PubMed ID: 35837772
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.
Forte TM; Ryan RO
Curr Drug Targets; 2015; 16(12):1274-80. PubMed ID: 26028042
[TBL] [Abstract][Full Text] [Related]
4. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers.
Feng Q; Baker SS; Liu W; Arbizu RA; Aljomah G; Khatib M; Nugent CA; Baker RD; Forte TM; Hu Y; Zhu L
Pathology; 2015 Jun; 47(4):341-8. PubMed ID: 25938357
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway.
Li R; Zhu W; Huang P; Yang Y; Luo F; Dai W; Shen L; Pei W; Huang X
Biomed Pharmacother; 2021 Sep; 141():111803. PubMed ID: 34146854
[TBL] [Abstract][Full Text] [Related]
6. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
7. Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters.
Guo J; Miao G; Zhang W; Shi H; Lai P; Xu Y; Zhang L; Chen G; Han Y; Zhao Y; Liu G; Zhang L; Wang Y; Huang W; Xian X
Theranostics; 2024; 14(5):2036-2057. PubMed ID: 38505614
[No Abstract] [Full Text] [Related]
8. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity.
Huang XS; Zhao SP; Hu M; Bai L; Zhang Q; Zhao W
Atherosclerosis; 2010 Jun; 210(2):563-8. PubMed ID: 20047745
[TBL] [Abstract][Full Text] [Related]
9. APOA5 gene expression in the human intestinal tissue and its response to in vitro exposure to fatty acid and fibrate.
Guardiola M; Alvaro A; Vallvé JC; Rosales R; Solà R; Girona J; Serra N; Duran P; Esteve E; Masana L; Ribalta J
Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):756-62. PubMed ID: 21489765
[TBL] [Abstract][Full Text] [Related]
10. APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects.
Jang Y; Chae JS; Kim OY; Park HJ; Kim JY; Paik JK; Lee SH; Lee JH
Atherosclerosis; 2010 Aug; 211(2):512-9. PubMed ID: 20392444
[TBL] [Abstract][Full Text] [Related]
11. Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.
Hahne P; Krempler F; Schaap FG; Soyal SM; Höffinger H; Miller K; Oberkofler H; Strobl W; Patsch W
J Intern Med; 2008 Nov; 264(5):452-62. PubMed ID: 18537870
[TBL] [Abstract][Full Text] [Related]
12. Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly through the apolipoprotein A5 pathway.
Li R; Chen LZ; Zhao W; Zhao SP; Huang XS
Biochem Biophys Res Commun; 2016 Sep; 478(3):1173-8. PubMed ID: 27544029
[TBL] [Abstract][Full Text] [Related]
13. FoxO3 regulates hepatic triglyceride metabolism via modulation of the expression of sterol regulatory-element binding protein 1c.
Wang L; Zhu X; Sun X; Yang X; Chang X; Xia M; Lu Y; Xia P; Yan H; Bian H; Gao X
Lipids Health Dis; 2019 Nov; 18(1):197. PubMed ID: 31729980
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
Dorfmeister B; Brandlhofer S; Schaap FG; Hermann M; Fürnsinn C; Hagerty BP; Stangl H; Patsch W; Strobl W
Diabetologia; 2006 Jun; 49(6):1324-32. PubMed ID: 16570166
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
VerHague MA; Cheng D; Weinberg RB; Shelness GS
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551
[TBL] [Abstract][Full Text] [Related]
16. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.
Su X; Kong Y; Peng DQ
Lipids Health Dis; 2018 Jul; 17(1):174. PubMed ID: 30053818
[TBL] [Abstract][Full Text] [Related]
17. [Metformin reduces plasma triglycerides in ob/ob obese mice via inhibiting the hepatic apoA5 expression].
Huang X; Li R; Chen L; Dai W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 42(12):1389-1394. PubMed ID: 29317579
[TBL] [Abstract][Full Text] [Related]
18. Palmitate induces fat accumulation by activating C/EBPβ-mediated G0S2 expression in HepG2 cells.
Zhao NQ; Li XY; Wang L; Feng ZL; Li XF; Wen YF; Han JX
World J Gastroenterol; 2017 Nov; 23(43):7705-7715. PubMed ID: 29209111
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of cyclic AMP response element-binding protein H response element in the human apolipoprotein A5 gene promoter.
Song KH; Park AY; Kim JE; Ma JY
Biomed Res Int; 2013; 2013():892491. PubMed ID: 23957007
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein A5 controls fructose-induced metabolic dysregulation in mice.
Ress C; Dobner J; Rufinatscha K; Staels B; Hofer M; Folie S; Radlinger B; Adolph TE; Rubin EM; Roden M; Tilg H; Kaser S
Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):972-978. PubMed ID: 33549451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
